Percheron Therapeutics (AWY0) Stock Statistics & Valuation Metrics
Total Valuation
Percheron Therapeutics has a market cap or net worth of EUR 3.73M. The enterprise value is -EUR 1.17M.
- Market Cap
- EUR 3.73M
- Enterprise Value
- -EUR 1.17M
Share Statistics
Percheron Therapeutics has 1,982,415,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,982,415,500
- Owned by Insiders
- 5.19%
- Owned by Institutions
- ―
Financial Efficiency
Percheron Therapeutics’s return on equity (ROE) is -0.64 and return on invested capital (ROIC) is -64.92%.
- Return on Equity (ROE)
- -0.64
- Return on Assets (ROA)
- -0.58
- Return on Invested Capital (ROIC)
- -64.92%
- Return on Capital Employed (ROCE)
- -0.75
- Revenue Per Employee
- 0
- Profits Per Employee
- -598.97K
- Employee Count
- 8
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Percheron Therapeutics is -0.73. Percheron Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -0.73
- PS Ratio
- 0.00
- PB Ratio
- 0.55
- Price to FCF
- -0.67
- Price to Operating Cash Flow
- -0.83
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Percheron Therapeutics had revenue of 0 and earned -4.79M in profits. Earnings per share was -0.00.
- Revenue
- 0
- Gross Profit
- -219.56K
- Operating Income
- -5.62M
- Pretax Income
- -5.49M
- Net Income
- -4.79M
- EBITDA
- -5.40M
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was -4.96M and capital expenditures -7,945, giving a free cash flow of -4.97M billion.
- Operating Cash Flow
- -4.96M
- Free Cash Flow
- -4.97M
- Free Cash Flow per Share
- -0.00
Dividends & Yields
Percheron Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -148.68%
- Earnings Yield
- -116.44%
Stock Price Statistics
- Beta
- 13.36
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Percheron Therapeutics upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 19, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- ―
Financial Position
Percheron Therapeutics as a current ratio of 7.64, with Debt / Equity ratio of 0.37%
- Current Ratio
- 7.64
- Quick Ratio
- 7.64
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.47
- Interest Coverage Ratio
- -366.34
Taxes
In the past 12 months, Percheron Therapeutics has paid -696.35K in taxes.
- Income Tax
- -696.35K
- Effective Tax Rate
- 0.13
Enterprise Valuation
Percheron Therapeutics EV to EBITDA ratio is -0.15, with an EV/FCF ratio of -0.16.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.15
- EV to Free Cash Flow
- -0.16
- EV to Operating Cash Flow
- -0.16
Balance Sheet
Percheron Therapeutics has EUR 4.05M in cash and marketable securities with EUR 27.79K in debt, giving a net cash position of EUR 4.02M billion.
- Cash & Marketable Securities
- EUR 4.05M
- Total Debt
- EUR 27.79K
- Net Cash
- EUR 4.02M
- Net Cash Per Share
- EUR 0.00
- Tangible Book Value Per Share
- EUR 0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Percheron Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 73.86%
Scores
- Smart Score
- 7
- AI Score
- ―